The current study evaluated the potential benefits of the SGLT2 inhibitor Dap on DKD in a diabetic mouse model, focusing primarily on the ability of Dap to influence the Th17/Treg cell imbalance. This evidence concerns the gene SLC5A2 and diabetic kidney disease.